THE DEVELOPMENT of neutralizing antibodies (NABs) against interferons is well described in patients with viral hepatitis and with some cancers that are treated with interferon.1 In patients with hepatitis or cancer, the development of NABs has been associated with reduction of interferon-related adverse effects (eg, fever, chills, and myalgia) and with the recurrence of disease activity. Treatment failure due to NABs in such patients has been much easier to identify, by measuring the more sensitive disease activity markers (eg, transaminase levels in patients with hepatitis or tumor or tumor markers in patients with cancer).
Rice G. The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta. Arch Neurol. 2001;58(8):1297-1298. doi:10.1001/archneur.58.8.1297